Zealand Pharma A/S (ZLDPF)
| Previous close | 86.75 |
| Open | 86.10 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 86.75 - 86.75 |
| 52-week range | 31.11 - 111.44 |
| Volume | |
| Avg. volume | 2,837 |
| Market cap | 5.402B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Zealand Pharma, Gap, Freshpet: Trending Tickers
Zealand Pharma (ZEAL.CO) stock skyrockets on positive results from a liver disease treatment trial. JPMorgan analysts upgrade retailer The Gap (GPS) to Neutral, raising the price target to $20. Pet food company Freshpet (FRPT) sees its stock jump after beating fourth-quarter earnings estimates and issuing strong sales guidance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
- Reuters
UPDATE 2-Zealand says US FDA turns down drug for low blood sugar in infants
Zealand Pharma said on Saturday that the U.S. Food and Drug Administration (FDA) had declined to approve its drug for preventing and treating low blood sugar in children with a genetic disorder after finding deficiencies at a third-party manufacturing facility. Zealand is seeking FDA approval for dasiglucagon, which it plans to use in patients aged seven days or older with congenital hyperinsulinism (CHI), a genetic disorder in which the pancreas secretes too much insulin. The Danish drugmaker said that the FDA did not state any immediate concerns about the clinical data package or safety of the drug, but had raised concerns about "deficiencies" it found at the third-party manufacturing facility after an inspection.
- Zacks
Zealand Pharma A/S (ZLDPF) is on the Move, Here's Why the Trend Could be Sustainable
Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
